Xior reported EPRA EPS of 1.01 that slightly beat our 1.00 expectation (excl. IFRIC costs). Xior NRI rose 4.0% yoy after its disposal program of FY24, but like-for-like growth remained high at 5.4%. LTV% also fell below 50% at 49.8%. Xior repeated its flat EPRA EPS outlook for FY25 of 2.21 per share. Xior expects an underlying strong FY25 thanks to a mix of factors: new assets + lfl growth of >5% and cost savings. The cost of debt decreased slightly from 3.10% (FY24) to 3.03%. The asset disposal...
Agfa-Gevaert NV signs new revolving credit facility - Regulated information - Contains inside information August 1, 2025 – 6.00 PM CET Regulated information - Contains inside information Agfa-Gevaert NV signs new revolving credit facility Mortsel, Belgium – August 1, 2025 – 6.00 p.m. CET Agfa-Gevaert NV has signed a new 3 year revolving credit facility of 180 million euro. The new facility will run until August 1, 2028. This new revolving credit facility will be used for working capital and general corporate purposes. It will replace the existing...
Agfa-Gevaert NV tekent nieuwe doorlopende kredietfaciliteit - Gereglementeerde informatie – Bevat voorwetenschap 1 augustus 2025 – 18u00 CET Gereglementeerde informatie – Bevat voorwetenschap Agfa-Gevaert NV tekent nieuwe doorlopende kredietfaciliteit Mortsel, België – 1 augustus 2025 – 18u00 CET Agfa-Gevaert NV heeft een nieuwe voor 3 jaar geldende doorlopende kredietfaciliteit getekend voor een bedrag van 180 miljoen euro. De nieuwe faciliteit loopt tot 1 augustus 2028. Deze nieuwe doorlopende kredietfaciliteit zal gebruikt worden voor werkkapitaal en algemene bedrijfsdoeleinden. Ze...
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at CER 12.3% R...
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025 Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 31 juli 2025 – 07.00 uur CET Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025 Fagron, de toonaangevende wereldwijde speler op het gebied van farmaceutische compounding, publiceert vandaag haar eerste halfjaarresultaten voor de periode eindigend op 30 juni 2025. Belangrijkste hoogtepunten Sterke omzetresultaten met een gerapporteerde omzetgroei van 10,9% (1...
We update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 27 January 2025, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune. The ING Benelux Fav...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.